Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Aurinia Pharmaceuticals Inc. (AUPH) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/03/2023 8-K Quarterly results
Docs: "AURINIA PHARMACEUTICALS REPORTS SECOND QUARTER AND SIX MONTHS 2023 FINANCIAL AND OPERATIONAL RESULTS"
02/28/2023 8-K Quarterly results
Docs: "AURINIA REPORTS FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL RESULTS AND COMPANY UPDATES"
08/04/2022 8-K Quarterly results
Docs: "AURINIA REPORTS SECOND QUARTER AND SIX MONTHS 2022 FINANCIAL AND OPERATIONAL RESULTS"
05/10/2022 8-K Quarterly results
02/28/2022 8-K Quarterly results
05/06/2021 8-K Quarterly results
11/10/2020 6-K Quarterly results
Docs: "AURINIA PHARMACEUTICALS INC. 6-K",
"Aurinia Reports Third Quarter 2020 Financial Results and Recent Operational Highlights"
08/11/2020 6-K Quarterly results
05/14/2020 6-K Quarterly results
03/05/2020 6-K Quarterly results
11/14/2019 6-K Quarterly results
08/06/2019 6-K Quarterly results
05/14/2019 6-K Quarterly results
Docs: "AURINIA PHARMACEUTICALS INC. 6-K",
"Aurinia Reports First Quarter 2019 Financial Results and Recent Operational Highlights - Conference call and webcast to be hosted today at 4:30pm EDT -"
03/19/2019 6-K Quarterly results
Docs: "AURINIA PHARMACEUTICALS INC. 6-K",
"Aurinia Reports Fourth Quarter and Full Year 2018 Financial Results and Operational Highlights"
11/08/2018 6-K Quarterly results
Docs: "AURINIA PHARMACEUTICALS INC. 6-K",
"Aurinia Reports Third Quarter Financial Results, Clinical Highlights and Corporate Development"
08/09/2018 6-K Quarterly results
Docs: "AURINIA PHARMACEUTICALS INC. 6-K",
"Aurinia Reports Second Quarter Financial Results and Operational Highlights AURORA Phase III Trial in lupus nephritis anticipated to complete enrollment ahead of schedule Trials in FSGS and Dry Eye initiated"
05/10/2018 6-K Quarterly results
Docs: "AURINIA PHARMACEUTICALS INC. 6-K",
"Aurinia Reports First Quarter Financial Results and Operational Highlights AURORA Phase III Trial in lupus nephritis remains on track Trials in FSGS and Dry Eye expected to begin in June 2018"
03/15/2018 6-K Quarterly results
Docs: "AURINIA PHARMACEUTICALS INC. 6-K",
"Aurinia Reports Fourth Quarter and Full Year 2017 Financial Results and Operational Highlights AURORA Phase III Trial in lupus nephritis on track Trials in FSGS and Dry Eye to begin in Q2 2018 Cash of $173.5 million as of December 31, 2017"
11/14/2017 6-K Quarterly results
Docs: "AURINIA PHARMACEUTICALS INC. 6-K",
"Aurinia Reports Third Quarter 2017 Financial Results and Provides Operational Highlights AURORA Phase III Trial in lupus nephritis on track Trials in FSGS, MCD and Dry Eye to begin in the first half of 2018 Cash of $182.4 million as of September 30, 2017"
08/10/2017 6-K Quarterly results
05/15/2017 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy